Anti-Therapeutic Action: Poor bioavailability

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

A 28-year-old woman developed a fungal infection called histoplasmosis after having a tooth extracted, with the infection spreading to her lungs and sinuses. She was initially given a common antifungal medication called itraconazole, but her condition continued to worsen despite increasing the dose. When doctors switched her to a stronger medication called liposomal amphotericin B given intravenously, she improved dramatically and recovered fully. This case shows the importance of recognizing when a standard fungal treatment is not working and switching to more aggressive therapy.

Read More »

Recent innovations and challenges in the treatment of fungal infections

Fungal infections are becoming more common and harder to treat due to drug resistance, especially in people with weakened immune systems. Current antifungal medications are becoming less effective because fungi are adapting to resist them, and these drugs can cause serious side effects. Scientists are developing new treatment strategies using combinations of existing drugs, engineered biological approaches, and specially designed delivery systems to overcome resistance and improve patient outcomes.

Read More »
Scroll to Top